MNPR Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stagepreclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.

Company profile

Chandler Drew Robinson
Fiscal year end
Monopar Therapeutics Australia Ltd • Monopar Therapeutics, SARL ...
IRS number

MNPR stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


12 Aug 21
18 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 24.29M 24.29M 24.29M 24.29M 24.29M 24.29M
Cash burn (monthly) 476.75K (positive/no burn) 697.47K 657.99K 468.71K 490.45K
Cash used (since last report) 1.72M n/a 2.52M 2.38M 1.69M 1.77M
Cash remaining 22.57M n/a 21.77M 21.92M 22.6M 22.52M
Runway (months of cash) 47.3 n/a 31.2 33.3 48.2 45.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Sep 21 Michael J Brown Common Stock Option exercise Acquire M No No 0 751 0 213,543
30 Sep 21 Michael J Brown RSU Common Stock Option exercise Dispose M No No 0 751 0 751
30 Sep 21 Chandler Robinson Common Stock Payment of exercise Dispose F No No 4.87 1,155 5.62K 26,758.8
30 Sep 21 Chandler Robinson Common Stock Option exercise Acquire M No No 0 3,941 0 27,913.8
30 Sep 21 Chandler Robinson RSU Common Stock Option exercise Dispose M No No 0 3,941 0 51,236
30 Sep 21 Klausner Arthur J Common Stock Option exercise Acquire M No No 0 751 0 8,543
30 Sep 21 Klausner Arthur J RSU Common Stock Option exercise Dispose M No No 0 751 0 751
30 Sep 21 Anderson Raymond Common Stock Option exercise Acquire M No No 0 751 0 4,543
30 Sep 21 Anderson Raymond RSU Common Stock Option exercise Dispose M No No 0 751 0 751
30 Sep 21 Starr Christopher M Common Stock Option exercise Acquire M No No 0 751 0 3,543

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

1.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 9 12 -25.0%
Opened positions 1 5 -80.0%
Closed positions 4 0 NEW
Increased positions 6 2 +200.0%
Reduced positions 1 2 -50.0%
13F shares
Current Prev Q Change
Total value 1.1M 1.2M -8.6%
Total shares 186.76K 194.13K -3.8%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Vanguard 97.46K $574K +116.2%
NTRS Northern Trust 36.11K $213K +0.3%
Geode Capital Management 28.76K $169K +9.0%
BLK Blackrock 15.05K $89K +34.0%
RY Royal Bank Of Canada 5.13K $30K -43.8%
MS Morgan Stanley 4K $24K +25.0%
Captrust Financial Advisors 170 $1K 0.0%
Paragon Wealth Strategies 58 $0 NEW
WFC Wells Fargo & Co. 27 $0 +42.1%
Proequities 0 $0
Largest transactions
Shares Bought/sold Change
Vanguard 97.46K +52.39K +116.2%
Marshall Wace 0 -47.65K EXIT
Citadel Advisors 0 -12.48K EXIT
RY Royal Bank Of Canada 5.13K -4K -43.8%
BLK Blackrock 15.05K +3.82K +34.0%
Geode Capital Management 28.76K +2.37K +9.0%
Tower Research Capital 0 -2.21K EXIT
MS Morgan Stanley 4K +800 +25.0%
UBS UBS Group AG - Registered Shares 0 -571 EXIT
NTRS Northern Trust 36.11K +105 +0.3%

Financial report summary

  • Even if we complete the clinical trials we discussed with the FDA, there is no guarantee that at the time of submission the FDA will accept our new drug application (“NDA”) based on the trials discussed.
  • As a company, we have never completed a clinical trial and have limited experience in completing regulatory filings and any delays in regulatory filings could materially affect our financial condition.
  • We may seek fast track designation for one or more of our current and future product candidates, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.
  • We, or any future collaborators, may not be able to obtain and maintain orphan drug exclusivity for our product candidates in the U.S. and Europe.
  • If serious adverse or undesirable side effects are identified during the development of our product candidates, we may abandon or limit our development or commercialization of such product candidates.
  • If we experience delays or difficulties in the enrollment of subjects to our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented, which could materially affect our financial condition.
  • If we or our licensees, development collaborators, or suppliers are unable to manufacture our products in sufficient quantities or at defined quality specifications, or are unable to obtain regulatory approvals for the manufacturing facility, we may be unable to develop and/or meet demand for our products and lose time to market and potential revenues.
  • It is uncertain whether product liability insurance will be adequate to address product liability claims, or that insurance against such claims will be affordable or available on acceptable terms in the future.
  • If the market opportunities for our current and potential future drug candidates are smaller than we believe they are, our ability to generate product revenues will be adversely affected and our business may suffer.
  • Corporate, non-profit, and academic collaborators may take actions (including lack of effective actions) to delay, prevent, or undermine the success of our products.
  • The termination of third-party licenses could adversely affect our rights to important compounds or technologies.
  • Data provided by collaborators and other parties upon which we rely have not been independently verified and could turn out to be inaccurate, misleading, or incomplete.
  • In certain cases, we may need to rely on a single supplier for a particular manufacturing material or service, and any interruption in or termination of service by such supplier could delay or disrupt the commercialization of our products.
  • Our Validive manufacturer is in the United Kingdom (“UK”), and it is unknown in the long-term how they will be impacted by Brexit; however, if they are negatively impacted, this could increase our manufacturing costs, delivery schedules, and adversely impact our financial condition.
  • Our contracted camsirubicin manufacturing plant is located outside of the U.S. and may be affected by imposed tariffs and regional geopolitical factors outside of its control, which may affect the supply of camsirubicin active pharmaceutical ingredient. If we need to enlist a new contract manufacturer and it will delay our camsirubicin clinical program with GEIS and may increase our cost in supporting the GEIS Phase 2 clinical trial.
  • We rely on third parties to conduct our non-clinical studies and our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize our current product candidates or any future products, on a timely basis or at all, and our financial condition will be adversely affected.
  • We have no experience as a company in commercializing any product. If we fail to obtain commercial expertise, upon product approval by regulatory agencies, our product launch and revenues could be delayed.
  • Our product development efforts are at an early stage. We have not yet undertaken any marketing efforts, and there can be no assurance that future anticipated market testing and analyses will validate our marketing strategy. We may need to modify the products, or we may not be successful in either developing or marketing those products.
  • If we are unable to establish relationships with licensees or collaborators to carry out sales, marketing, and distribution functions or to create effective marketing, sales, and distribution capabilities, we will be unable to market our products successfully.
  • Commercial success of our product candidates will depend on the acceptance of these products by physicians, payers, and patients.
  • Our products may not be accepted for reimbursement or adequately reimbursed by third-party payers.
  • The effects of economic and political pressure to lower pharmaceutical prices are a major threat to the economic viability of new research-based pharmaceutical products, and any significant decrease in drug prices could materially and adversely affect our prospects.
  • If we obtain FDA approval for any of our product candidates, we will be subject to various federal and state fraud and abuse laws; these laws may impact, among other things, our proposed sales, marketing and education programs. Fraud and abuse laws are expected to increase in breadth and in detail, which will likely increase our operating costs and the complexity of our programs to ensure compliance with such enhanced laws.
  • If our operations are found to be in violation of any of the federal and state fraud and abuse laws or any other governmental regulations that apply to us, we may be subject to criminal actions and significant civil monetary penalties, which would adversely affect our ability to operate our business and our results of operations.
  • Negotiated prices for our products covered by a Part D prescription drug plan and other government programs will be lower than the prices we might otherwise obtain.
  • If we and our third-party licensors do not obtain and preserve protection for our respective intellectual property rights, our competitors may be able to take advantage of our (and our licensors’) development efforts to develop competing drugs.
  • The patent protection we obtain and preserve for our product candidates may not be sufficient to provide us with any material competitive advantage.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • Intellectual property disputes could require us to spend time and money to address such disputes and could limit our intellectual property rights.
  • We may not be able to enforce our intellectual property rights throughout the world.
  • Changes to the patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If we fail to comply with our obligations under any license, collaboration or other intellectual property-related agreements, we may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting our current or future technologies or drug candidates or we could lose certain rights to grant sublicenses.
  • Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of our business.
  • Intellectual property rights of third parties could adversely affect our ability to commercialize our current or future technologies or drug candidates, and we might be required to litigate or obtain licenses from third parties to develop or market our current or future technologies or drug candidates, which may not be available on commercially reasonable terms, or at all.
  • As a recently established entity, we have a limited operating history.
  • If we lose key management leadership, and/or scientific personnel, and if we cannot recruit qualified employees, managers, directors, officers, or other significant personnel, it is highly likely that we will experience program delays and increases in compensation costs, and our business will be materially disrupted.
  • We incur costs as a result of operating as a stock trading public company, and our management is required to devote substantial time to investor relations, information and communication to the public, and related compliance initiatives and corporate governance practices.
  • Despite ongoing compliance training and periodic education, our employees and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could result in delays or terminations of our development programs and adversely affect our business.
  • We are an emerging growth company and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.
  • Competition and technological change may make our product candidates less competitive or obsolete.
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  • We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.
  • Our business and operations are vulnerable to computer system failures, cyber-attacks or deficiencies in our cyber-security, which could increase our expenses, divert the attention of our management and key personnel away from our business operations and adversely affect our results of operations.
  • Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business.
  • If we, our contract research organizations ("CROs") or our IT vendors experience security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of personal data, we may face costs, significant liabilities, harm to our brand and business disruption.
  • If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
  • We have limited the liability of and indemnified our directors and officers.
  • Future legislation or executive or private sector actions may increase the difficulty and cost for us to commercialize our products and adversely affect the prices obtained for such products.
  • Even if we are able to commercialize any drug candidate, such drug candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.
  • Politically divided governmental actions and related political actions outside of government can impact the FDA’s role in the timely and effective review of new pharmaceutical products in the U.S. and our business may be adversely impacted.
  • Effective collaboration with the FDA’s Center for Drug Evaluation and Research (“CDER”) for the approval of drug candidates is a highly demanding process which can result in increased time and expense to gain approvals.
  • Future tax reform measures may negatively impact our financial position.
  • Foreign currency exchange rates may adversely affect our consolidated financial statements.
  • Our anticipated operating expenses and capital expenditures over the next year are based upon our management’s estimates of possible future events. Actual amounts and the cost of new conditions could differ materially from those estimated by our management.
  • The financial and operational projections that we may make from time to time are subject to inherent risks.
  • Our present and potential future international operations may expose us to business, political, operational, and financial risks associated with doing business outside of the United States.
  • We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business.
  • Existing and new investors will experience dilution as a result of future sales or issuances of our common stock and future option exercises under our 2016 Stock Incentive Plan and any amendments to the plan.
  • Holders of the shares of our common stock will have no control of our operations or of decisions on major transactions.
  • Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a de-listing of our common stock.
  • We may become involved in securities class action litigation that could divert management’s attention and harm our business.
  • Substantial amounts of our outstanding shares may be sold into the market. If there are substantial sales of shares of our common stock, the price of our common stock could decline.
  • Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
  • We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.
  • There can be no assurance that we will ever provide liquidity to our investors through a sale of our Company.
  • Delaware law and provisions in our amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the potential trading price of our common stock.
Content analysis
H.S. sophomore Avg
New words: aberrant, acid, America, American, appointed, Asia, begun, biopsy, blockbuster, bound, Celgene, characterized, choice, Cittadine, clearance, composition, concept, constrained, Cooperation, Costa, CSI, device, direction, Dr, efficiency, EMEA, Employment, Europe, explore, Filho, formatted, Fortune, founding, guide, induction, inline, invent, Investigational, isotope, joined, Jose, knowledge, Latin, lenalidomide, light, long, MBA, MD, Medtronic, Merck, metal, newly, NUS, Octavio, overseeing, oversight, Pacific, Page, paragraph, PCT, PCTA, pegfilgrastim, Pinto, played, potency, premier, priority, purity, radiochemical, Radiopharmaceutical, radiotherapeutic, Rafael, ranked, rational, Region, resistant, REVLIMID, role, scarcity, Sensant, Singapore, SonarMed, startup, surging, top, Treaty, unexpected
Removed: began, China, designated, family, home, nominal, open, remain, strain, surfaced